Zhitong Financial APP learned that$CANSINOBIO-B (06185.HK)$It fell more than 22% to HK $109.9, with a turnover of nearly HK $50 million.

In the news, CANSINOBIO announced that the company was concerned about the recent media attention to the company's inhaled COVID-19 vaccine, which was gradually available for appointment and use in many provinces and cities across the country due to the promotion of the commercialization of the inhaled COVID-19 vaccine. Based on the current immunization strategy and the high vaccination rate of enhanced injections in China, the company expects that the inhaled recombinant novel coronavirus vaccine (adenovirus type 5 vector) will not lead to a significant increase in the company's performance.